On January 22, 2024, BioNTech SE announced that the first patient with metastatic breast cancer has been treated in a pivotal Phase 3 trial for its next-generation antibody-drug conjugate BNT323/DB-1303, aimed at HER2 targeting.
AI Assistant
BIONTECH SE
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.